Independent Safety Panel

An Independent Safety Panel has been appointed to independently safeguard the interests of trial participants, assess the aggregate safety data across the MiP trials and provide objective, independent scientific advice to the Safety Working Group and the Executive Committee.

The Independent Safety Panel consists of 7 members who are impartial and independent to the studies. The Independent Safety Panel includes experts in or representatives of the fields of: statistics, epidemiology (perinatal), pharmacology, teratology/toxicology, pharmacovigilance, ethics and experience of trials in developing countries.


Sir Alasdair Breckenridge (Chair) - Chairman, Medicines and Healthcare Product Regulatory Agency, UK

Alex Dodoo - University of Ghana Medical School, Accra, Ghana

Bernard Nahlen – Deputy Director, USAID, President’s Malaria Initiative, Washington, US

Elisabeth Elefant - CRAT Hôpital Trousseau, Paris, France

Thomas Smith - Biostatistics and Basic Epidemiology, Swiss Tropical and Public Health Institute, Switzerland

Godfrey B. Tangwa - University of Yaoundé, Cameroon

Zul Premji - Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania